Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Introduction and first vote

Date

09 Oct 2016

Session

Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?

Presenters

Michael Gnant

Authors

M. Gnant

Author affiliations

  • Vienna University, Vienna/AT
More

Resources

Resources from the same session

Yes

Presenter: Angelo di Leo

Session: Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?

Resources:

Presentation

Webcast

Second vote and conclusions

Presenter: Michael Gnant

Session: Should combined endocrine therapy with targeted agents now be the standard of care for ER+ metastatic breast cancer?

Resources:

Presentation

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings